Fileclosp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Fileclo is an advanced-technology company that develops and commercializes research projects involving salinomycin. Its goals include developing cytostatic drugs without side effects, chemotherapy for preventive use, and methods to combat cancers currently considered incurable.
Financials
Revenue history (in k)
Filing timeliness
5 of 6 financial statements were filed late (the longest delay 84 days for 2023).
- 2025filed
- 202406/10/2025
- 202307/10/2024
- 202211/08/2023
- 202124/08/2022
- 202010/12/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the President of the Management Board is authorized to perform legal acts and make declarations on behalf of the company independently, or two members of the management board jointly.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Witold Adam Mozgaage 52 | 45 | $607.78 | 12.2616% |
Jacek Piotr Olczakage 56 | 45 | $607.78 | 12.2616% |
Danuta Olejniczak Michniewiczage 77 | 37 | $499.73 | 10.0817% |
Przemysław Kazimierz Pilaszekage 50 | 240 | $3,241.49 | 65.3951% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-06-01.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
7 public aid cases recorded, with a total value of $8,351,971.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 13, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $179.8K$179,765 | Marszałek Województwa Łódzkiego | |
| Aug 10, 2023 | Aid for research and development projects: industrial research | $2M$2,044,462 | Prezes Agencji Badań Medycznych | |
| Aug 10, 2023 | Aid for research and development projects: experimental development | $880.4K$880,395 | Prezes Agencji Badań Medycznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-05-01 | Implementation of an innovation involving a technology for producing high-purity salinomycin | $201.1K$201,126 | European Funds for Łódzkie 2021-2027 | |
| 2020-03-01 | Development of a new anticancer therapeutic with high activity and selectivity compared with currently used cytostatic drugs | $5.2M$5,171,466 | Operational Programme Smart Growth | |
| 2020-01-02 | Salinomycin derivatives with a reduced double bond as precursors of drugs for cancer therapy. | $50,294$50,294 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| Aslab ScienceP.S.A. | $1,504,132.17 | aslabsci.com | ||
| Scope FluidicsS.A. | $1,264,188.85 | scopefluidics.com | ||
| Pikralidasp. z o.o. | $1,151,165.63 | pikralida.eu | ||
| Bioresearch Groupsp. z o.o. | $776,186.19 | bioresearch.pl | ||
| Scientia Crosp. z o.o. | $607,622.19 | scientiacro.com | ||
| FamicordtxS.A. | $589,673.84 | famicordtx.com | ||
| CTI Clinical Trial and Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | ||
| Innotech4lifesp. z o.o. | $488,597.55 | innotech4life.pl | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl |
Change history
| Date | Event | |
|---|---|---|
| 2018-12-17 | Share capital increase (16,500.00 PLN → 18,350.00 PLN) | |
| 2018-10-17 | Share capital increase (10,000.00 PLN → 16,500.00 PLN) | |
| 2018-04-30 | Entered in the register |
FAQ
Last updated: 2026-04-06